Epigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer

dc.contributor.authorPiqué, Laia
dc.contributor.authorMartínez de Paz, Alexia
dc.contributor.authorPiñeyro, David
dc.contributor.authorMartínez Cardús, Anna
dc.contributor.authorCastro de Moura, Manuel
dc.contributor.authorLlinàs-Arias, Pere
dc.contributor.authorSetién, Fernando
dc.contributor.authorGómez Miragaya, Jorge
dc.contributor.authorGonzález Suárez, Eva
dc.contributor.authorSigurdsson, Stefan
dc.contributor.authorJonasson, Jon G.
dc.contributor.authorVillanueva Garatachea, Alberto
dc.contributor.authorVidal-Bel, August
dc.contributor.authorDavalos, Veronica
dc.contributor.authorEsteller, Manel
dc.date.accessioned2020-04-20T13:45:10Z
dc.date.available2020-04-20T13:45:10Z
dc.date.issued2019-11-01
dc.date.updated2020-04-20T13:45:10Z
dc.description.abstractHuman tumors show altered patterns of protein isoforms that can be related to the dysregulation of messenger RNA alternative splicing also observed in transformed cells. Although somatic mutations in core spliceosome components and their associated factors have been described in some cases, almost nothing is known about the contribution of distorted epigenetic patterns to aberrant splicing. Herein, we show that the splicing RNA-binding protein CELF2 is targeted by promoter hypermethylation-associated transcriptional silencing in human cancer. Focusing on the context of breast cancer, we also demonstrate that CELF2 restoration has growth-inhibitory effects and that its epigenetic loss induces an aberrant downstream pattern of alternative splicing, affecting key genes in breast cancer biology such as the autophagy factor ULK1 and the apoptotic protein CARD10. Furthermore, the presence of CELF2 hypermethylation in the clinical setting is associated with shorter overall survival of the breast cancer patients carrying this epigenetic lesion.
dc.format.extent7 p.
dc.format.mimetypeapplication/pdf
dc.identifier.idgrec694462
dc.identifier.issn0950-9232
dc.identifier.pmid31409895
dc.identifier.urihttps://hdl.handle.net/2445/156079
dc.language.isoeng
dc.publisherMacmillan Publishers
dc.relation.isformatofReproducció del document publicat a: https://doi.org/10.1038/s41388-019-0936-x
dc.relation.ispartofOncogene, 2019, vol. 38, num. 45, p. 7106-7112
dc.relation.urihttps://doi.org/10.1038/s41388-019-0936-x
dc.rightscc-by (c) Piqué et al., 2019
dc.rights.accessRightsinfo:eu-repo/semantics/openAccess
dc.rights.urihttp://creativecommons.org/licenses/by/3.0/es/*
dc.sourceArticles publicats en revistes (Ciències Fisiològiques)
dc.subject.classificationCàncer de mama
dc.subject.classificationProteïnes
dc.subject.classificationTeixit nerviós
dc.subject.classificationADN
dc.subject.classificationMetilació
dc.subject.classificationRNA
dc.subject.otherBreast cancer
dc.subject.otherProteins
dc.subject.otherNerve tissue
dc.subject.otherDNA
dc.subject.otherMethylation
dc.subject.otherRNA
dc.titleEpigenetic inactivation of the splicing RNA-binding protein CELF2 in human breast cancer
dc.typeinfo:eu-repo/semantics/article
dc.typeinfo:eu-repo/semantics/publishedVersion

Fitxers

Paquet original

Mostrant 1 - 1 de 1
Carregant...
Miniatura
Nom:
694462.pdf
Mida:
979.47 KB
Format:
Adobe Portable Document Format